Kyverna Therapeutics (KYTX) & Its Rivals Head to Head Comparison

Kyverna Therapeutics (NASDAQ:KYTX) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Kyverna Therapeutics to similar companies based on the strength of its risk, profitability, analyst recommendations, dividends, institutional ownership, earnings and valuation.

Insider & Institutional Ownership

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Kyverna Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyverna Therapeutics	$7.03 million	-$60.37 million	-0.58
Kyverna Therapeutics Competitors	$574.62 million	-$70.96 million	-0.15

Kyverna Therapeutics’ rivals have higher revenue, but lower earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Kyverna Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-51.12%	-37.91%
Kyverna Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Analyst Ratings

This is a summary of recent recommendations for Kyverna Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	0	1	4	1	3.00
Kyverna Therapeutics Competitors	1924	5382	13923	296	2.58

Kyverna Therapeutics presently has a consensus target price of $18.40, suggesting a potential upside of 820.00%. As a group, “Biological products, except diagnostic” companies have a potential upside of 102.90%. Given Kyverna Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Kyverna Therapeutics is more favorable than its rivals.

Summary

Kyverna Therapeutics beats its rivals on 8 of the 12 factors compared.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.